PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma Completes Regular Quarterly Dividend Payment
PDL BioPharma Provides Third Quarter 2014 Revenue Guidance of $165 Million
PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results
PDL BioPharma Announces Plans to Issue Second Quarter Financial Results After Market Today and Reschedules Earnings Call for Tuesday, August 19 at 4:30pm EDT